Dry Powder for Intranasal Delivery

DATE
21 May 2025
TIME
08:00 PDT, 11:00 EDT, 16:00 BST, 17:00 CEST
Duration: 60 Minutes

Overview

Intranasal delivery of dry powder has many potential applications, including local, systemic, and nose-to-brain treatments. The market for oral inhalation has already shifted substantially towards dry powders as they offer benefits including shelf stability, dose range, efficiency of delivery, and ease of use. These benefits are also anticipated for intranasally delivered dry powders.

Importantly, intranasal dry powders may offer a non-invasive alternative for the delivery of biologics. One previous limitation on the adoption of this technology has been the inefficiency of spray-drying of large aqueous droplets. This webinar will explore a simple formulation strategy, and the ways in which the spray drying process can be tailored to produce right-sized particles with a high yield, at an appropriate scale for clinical and commercial production.

Key Learning Objectives:
  • Formulating for nasal delivery of dry powder
  • Achieving target particle size via spray drying
  • Scale-up considerations
  • Characterization of nasal powders
Who Should Attend:
  • Drug product specialists
  • Chemistry, manufacturing, and controls (CMC) leads
  • Respiratory drug delivery leaders
  • Pharmaceutical consultants

Speakers

Cameron Kadleck
Lead Research Scientist,
Lonza
Cody Prather
Senior Research Engineer,
Lonza
Ann Thayer
Contributing Editor,
C&EN Media Group

Registration

*By submitting this form, you agree to receive more information on related products and services from the American Chemical Society and its sponsor via email. You understand that you can withdraw your consent at any time. ACS takes your privacy seriously. For more information, please see the ACS Privacy Policy.
Brought to you by:
Lonza logo

© 2025 American Chemical Society, 1155 16th St NW, Washington, DC 20036, USA. View our Privacy Policy